52 Week Range
As of on the Bolsa de Valores do Estado de Sao Paulo ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Brazil's Biotoscana Appoints Claudio Coracini As Interim CEO After Agreement To Sell Control To Knight Therapeutics- Filing
Knight Therapeutics To Acquire Grupo Biotoscana
Biotoscana Investments SA is a Luxembourg-based company engaged in the healthcare industry. The Company develops, manufactures and distributes pharmaceutical products. The Company offers drugs for the treatment of infectious and rare diseases, oncology, onco-hematology, special treatments and immunology, among others. Its product development pipeline is divided into two business models: partnership product development, which is focused on building relationships to license and commercialize products that are new to Latin America, and internal product development, which is focused on studying, designing, formulating and manufacturing branded generic products. Apart from the Luxembourg, the Company operates worldwide in a number of countries, including Peru, Argentina and Ecuador, among others.
Biotechnology & Drugs
70, Route d'Esch
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Canada's Knight Therapeutics Inc and shareholders of Biotoscana Investments expect to conclude transfer of control of the Latin American pharmaceutical company by Nov. 29, the latter said in a securities filing on Monday.
Knight Therapeutics <GUD.TO> will buy Brazilian pharmaceutical company Biotoscana Investments <GBIO33.SA> in a deal valued at 1.16 billion reais ($281 million) that will create a pharmaceutical platform in fast growing markets in Latin America.
Shares in Canada's Knight Therapeutics were up 9% in Toronto after the announcement of acquisition of Latin American pharmaceutical company Biotoscana Investments earlier on Monday.
Latin American pharmaceutical company Biotoscana Investments <GBIO33.SA> confirmed that its shareholders were in talks with investors about a sale, according to a securities filing on Monday.
Canada's Knight Terapeutics <GUD.TO> and Brazilian pharmaceuticals company Eurofarma are interested in acquiring control of Brazilian pharmaceutical company Biotoscana Investments SA <GBIO33.SA>, one source with knowledge of the matter said.
Canada's Knight Terapeutics and Brazilian pharmaceuticals company Eurofarma are interested in acquiring control of Brazilian pharmaceutical company Biotoscana Investments SA, one source with knowledge of the matter said.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.